We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Bristol Myers Squibb (BMY - Free Report) will report quarterly earnings of $1.59 per share in its upcoming release, pointing to a year-over-year increase of 8.9%. It is anticipated that revenues will amount to $11.67 billion, exhibiting a decrease of 4.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Bristol Myers metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Net Sales- Zeposia' will reach $156.09 million. The estimate suggests a change of +4.1% year over year.
Analysts predict that the 'Net Sales- Orencia' will reach $940.44 million. The estimate indicates a year-over-year change of -2.3%.
The consensus estimate for 'Net Sales- Eliquis' stands at $4.00 billion. The estimate points to a change of +8.7% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Yervoy' reaching $725.82 million. The estimate indicates a change of -0.3% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Abraxane- U.S.' will reach $11.33 million. The estimate indicates a year-over-year change of -65.7%.
According to the collective judgment of analysts, 'Net Sales- Opdivo- U.S.' should come in at $1.33 billion. The estimate suggests a change of -11.6% year over year.
Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- U.S.' should arrive at $157.65 million. The estimate points to a change of -73% from the year-ago quarter.
Analysts forecast 'Net Sales- Pomalyst/Imnovid- International' to reach $52.98 million. The estimate suggests a change of -57.3% year over year.
The combined assessment of analysts suggests that 'Net Sales- Revlimid- U.S.' will likely reach $116.34 million. The estimate suggests a change of -84.1% year over year.
Analysts expect 'Net Sales- Revlimid- International' to come in at $58.84 million. The estimate points to a change of -44.5% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Reblozyl- U.S.' at $516.22 million. The estimate points to a change of +14% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Reblozyl- International' of $138.36 million. The estimate indicates a change of +21.4% from the prior-year quarter.
Shares of Bristol Myers have demonstrated returns of +8% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), BMY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Wall Street analysts forecast that Bristol Myers Squibb (BMY - Free Report) will report quarterly earnings of $1.59 per share in its upcoming release, pointing to a year-over-year increase of 8.9%. It is anticipated that revenues will amount to $11.67 billion, exhibiting a decrease of 4.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Bristol Myers metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Net Sales- Zeposia' will reach $156.09 million. The estimate suggests a change of +4.1% year over year.
Analysts predict that the 'Net Sales- Orencia' will reach $940.44 million. The estimate indicates a year-over-year change of -2.3%.
The consensus estimate for 'Net Sales- Eliquis' stands at $4.00 billion. The estimate points to a change of +8.7% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Yervoy' reaching $725.82 million. The estimate indicates a change of -0.3% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Abraxane- U.S.' will reach $11.33 million. The estimate indicates a year-over-year change of -65.7%.
According to the collective judgment of analysts, 'Net Sales- Opdivo- U.S.' should come in at $1.33 billion. The estimate suggests a change of -11.6% year over year.
Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- U.S.' should arrive at $157.65 million. The estimate points to a change of -73% from the year-ago quarter.
Analysts forecast 'Net Sales- Pomalyst/Imnovid- International' to reach $52.98 million. The estimate suggests a change of -57.3% year over year.
The combined assessment of analysts suggests that 'Net Sales- Revlimid- U.S.' will likely reach $116.34 million. The estimate suggests a change of -84.1% year over year.
Analysts expect 'Net Sales- Revlimid- International' to come in at $58.84 million. The estimate points to a change of -44.5% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Reblozyl- U.S.' at $516.22 million. The estimate points to a change of +14% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Reblozyl- International' of $138.36 million. The estimate indicates a change of +21.4% from the prior-year quarter.
View all Key Company Metrics for Bristol Myers here>>>Shares of Bristol Myers have demonstrated returns of +8% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), BMY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .